Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone855-698-8887
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90.64 million
Profitability
Miscellaneous
Employees454
Next Earnings Date11/18/2019 (Estimated)
OptionableNot Optionable
Guardant Health (NASDAQ:GH) Frequently Asked Questions
What is Guardant Health's stock symbol?
Guardant Health trades on the NASDAQ under the ticker symbol "GH."
How were Guardant Health's earnings last quarter?
Guardant Health Inc (NASDAQ:GH) issued its earnings results on Tuesday, August, 6th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.21. The business had revenue of $53.98 million for the quarter, compared to analyst estimates of $35.97 million. Guardant Health had a negative net margin of 60.08% and a negative return on equity of 22.93%. The firm's revenue was up 178.5% on a year-over-year basis. During the same period in the previous year, the business earned ($1.75) EPS. View Guardant Health's Earnings History.
When is Guardant Health's next earnings date?
What guidance has Guardant Health issued on next quarter's earnings?
Guardant Health updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180-190 million, compared to the consensus revenue estimate of $148.52 million.
What price target have analysts set for GH?
6 analysts have issued 1 year price targets for Guardant Health's shares. Their forecasts range from $84.00 to $135.00. On average, they anticipate Guardant Health's share price to reach $113.50 in the next twelve months. This suggests a possible upside of 11.8% from the stock's current price. View Analyst Price Targets for Guardant Health.
What is the consensus analysts' recommendation for Guardant Health?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Guardant Health.
Has Guardant Health been receiving favorable news coverage?
News headlines about GH stock have been trending negative recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Guardant Health earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Guardant Health.
Are investors shorting Guardant Health?
Guardant Health saw a drop in short interest in the month of July. As of July 31st, there was short interest totalling 2,891,700 shares, a drop of 13.2% from the June 30th total of 3,330,500 shares. Based on an average trading volume of 1,090,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 10.0% of the company's stock are short sold. View Guardant Health's Current Options Chain.
Who are some of Guardant Health's key competitors?
Some companies that are related to Guardant Health include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Personalis (PSNL), Celcuity (CELC), Fulgent Genetics (FLGT), Enzo Biochem (ENZ), PotNetwork (POTN) and Psychemedics (PMD).
What other stocks do shareholders of Guardant Health own?
Who are Guardant Health's key executives?
Guardant Health's management team includes the folowing people:
- Mr. AmirAli Talasaz, Chairman, Pres & COO (Age 40)
- Dr. Helmy Eltoukhy Ph.D., Co-Founder, CEO & Director (Age 40)
- Mr. Michael J. Wiley, Chief Legal Officer (Age 44)
- Mr. Derek A. Bertocci, Chief Financial Officer (Age 65)
- Dr. Richard B. Lanman, Chief Medical Officer (Age 64)
When did Guardant Health IPO?
(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.
Who are Guardant Health's major shareholders?
Guardant Health's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Morgan Stanley (5.18%), Vanguard Group Inc. (3.11%), Jennison Associates LLC (3.16%), Jennison Associates LLC (3.16%), BlackRock Inc. (2.43%) and Price T Rowe Associates Inc. MD (1.88%). Company insiders that own Guardant Health stock include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman and Vision Fund (Aiv M1) Softbank. View Institutional Ownership Trends for Guardant Health.
Which institutional investors are selling Guardant Health stock?
GH stock was sold by a variety of institutional investors in the last quarter, including Natixis, NumerixS Investment Technologies Inc, Bamco Inc. NY, Atika Capital Management LLC, Man Group plc, Essex Investment Management Co. LLC, First Midwest Bank Trust Division and Ladenburg Thalmann Financial Services Inc.. Company insiders that have sold Guardant Health company stock in the last year include Amirali Talasaz, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley and Richard B Lanman. View Insider Buying and Selling for Guardant Health.
Which institutional investors are buying Guardant Health stock?
GH stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Jennison Associates LLC, Jennison Associates LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Coatue Management LLC, BlackRock Inc. and Price T Rowe Associates Inc. MD. View Insider Buying and Selling for Guardant Health.
How do I buy shares of Guardant Health?
Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Guardant Health's stock price today?
One share of GH stock can currently be purchased for approximately $101.52.
How big of a company is Guardant Health?
Guardant Health has a market capitalization of $9.44 billion and generates $90.64 million in revenue each year. The company earns $-85,060,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. Guardant Health employs 454 workers across the globe.View Additional Information About Guardant Health.
What is Guardant Health's official website?
How can I contact Guardant Health?
Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company can be reached via phone at 855-698-8887.
MarketBeat Community Rating for Guardant Health (NASDAQ GH)
MarketBeat's community ratings are surveys of what our community members think about Guardant Health and other stocks. Vote "Outperform" if you believe GH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GH will underperform the S&P 500 over the long term. You may vote once every thirty days.
